Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Figure 1and Figure 2depict the classic lesions of urticaria multiforme. Urticaria multiforme, a form of acute annular urticaria, is an allergic hypersensitivity reaction mediated by histamine that may be IgE dependent or independent.1 The lesions are annular and polycyclic. They blanch with pressure and may display a central purplish or dusky hue. Because of similarities in the appearance of the rash, urticaria multiforme is often misdiagnosed as erythema multiforme and, less commonly, as serum sickness.
Abdomen.
Feet.
The term urticaria multiformewas proposed1 to describe this form of annular urticaria2 - 3 to emphasize the clinical manifestations that differentiate it from erythema multiforme. The lesions of urticaria multiforme may have dusky skin changes in central areas of polycyclic lesions, but these changes disappear without leaving the “bruising” that is commonly seen with erythema multiforme. True necrosis or blistering of the skin is never seen with urticaria multiforme and there is no associated mucous membrane involvement. Also, the lesions of urticaria multiforme are evanescent, with individual lesions lasting less than 24 hours, which further distinguishes it from the fixed lesions of erythema multiforme. The presence of dermatographism can also help to support the diagnosis of urticaria multiforme. Because urticaria multiforme is commonly associated with facial or acral edema it may also be confused with serum sickness–like reactions.1 ,3 - 4 Although swelling of the feet may make walking painful and difficult, true arthralgias or arthritis are not associated with urticaria multiforme. Importantly, the angioedema present in urticaria multiforme has not been associated with laryngoedema and has not been reported to be associated with food allergy.1 ,5 Suggested treatment for urticaria multiforme involves complete histamine receptor blockage. Long-duration H1blockers (such as cetirizine hydrochloride) should be given in association with H2blockers (such as ranitidine) with breakthrough relief as needed by diphenhydramine or hydroxyzine hydrochloride. Most patients have symptom relief with this combination within a few days to 2 weeks.1 Steroids should be reserved for patients who remain severely symptomatic despite antihistamine therapy. Treatment is largely symptomatic, as episodes of urticaria multiforme are self-resolving within 8 to 10 days.
Urticaria among children is more commonly associated with infectious rather than allergic etiologies.3 - 4 As a subset of urticarial eruptions, urticaria multiforme is also commonly associated with infection. In 1 retrospective study, 17% of patients with urticaria multiforme had laboratory-confirmed infection, including 1 patient with Mycoplasma pneumoniaepneumonia.1
The patient presented herein had clinical and radiographic findings consistent with pneumonia. His chest radiograph revealed a patchy opacity at the left lung base (Figure 3). Nasopharyngeal aspirate testing by polymerase chain reaction (PCR) confirmed the diagnosis of M pneumoniae. M pneumoniaehas also been associated with extrapulmonary complications, including myocarditis, pericarditis, encephalitis, aseptic meningitis, transverse myelitis, Guillain-Barre syndrome, hemolytic anemia, myalgias, and rash.6 M pneumoniaeis the main cause of erythematous rash in the setting of pneumonia and is associated with both erythema multiforme and Stevens-Johnson syndrome.6 - 8 However, M pneumoniaeis also associated with urticaria, as seen in the patient presented herein.1 ,6
Testing for M pneumoniaehas recently shifted to PCR techniques; however, some authors suggest that serologic studies should be performed in conjunction with PCR testing to increase the overall sensitivity of disease detection.9 - 10 Treatment for M pneumoniaeincludes tetracyclines, macrolides, or fluoroquinolones.8
The patient presented herein was treated with cetirizine and ranitidine with additional diphenhydramine as needed for his urticaria as well as azithromycin for M pneumoniaepneumonia. The symptoms began to resolve at the time of discharge 2 days later.
Return to Article .
Correspondence:Sage R. Myers, MD, Children's Hospital of Philadelphia, Emergency Medicine Offices, A-level, Main Bldg, AS01, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104 (myerss@email.chop.edu).
Accepted for Publication:July 31, 2009.
Author Contributions:Study concept and design: Myers and Lavelle. Acquisition of data: Myers. Analysis and interpretation of data: Myers. Drafting of the manuscript: Myers. Critical revision of the manuscript for important intellectual content: Myers and Lavelle. Administrative, technical, and material support: Myers. Study supervision: Lavelle.
Financial Disclosure:None reported.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Archives of Pediatrics and Adolescent Medicine editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.